These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25431070)

  • 1. Targeted toxicants to dopaminergic neuronal cell death.
    Jin H; Kanthasamy A; Harischandra DS; Anantharam V; Rana A; Kanthasamy A
    Methods Mol Biol; 2015; 1254():239-52. PubMed ID: 25431070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease.
    Liu Z; Qiu AW; Huang Y; Yang Y; Chen JN; Gu TT; Cao BB; Qiu YH; Peng YP
    Brain Behav Immun; 2019 Oct; 81():630-645. PubMed ID: 31351185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TrkB-positive dopaminergic neurons are less sensitive to MPTP insult in the substantia nigra of adult C57/BL mice.
    Ding YX; Xia Y; Jiao XY; Duan L; Yu J; Wang X; Chen LW
    Neurochem Res; 2011 Oct; 36(10):1759-66. PubMed ID: 21562748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DJ-1-dependent protective activity of DJ-1-binding compound no. 23 against neuronal cell death in MPTP-treated mouse model of Parkinson's disease.
    Takahashi-Niki K; Inafune A; Michitani N; Hatakeyama Y; Suzuki K; Sasaki M; Kitamura Y; Niki T; Iguchi-Ariga SM; Ariga H
    J Pharmacol Sci; 2015 Mar; 127(3):305-10. PubMed ID: 25837927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial permeability transition pore component cyclophilin D distinguishes nigrostriatal dopaminergic death paradigms in the MPTP mouse model of Parkinson's disease.
    Thomas B; Banerjee R; Starkova NN; Zhang SF; Calingasan NY; Yang L; Wille E; Lorenzo BJ; Ho DJ; Beal MF; Starkov A
    Antioxid Redox Signal; 2012 May; 16(9):855-68. PubMed ID: 21529244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective effects of total flavonoid fraction of the Epimedium koreanum Nakai extract on dopaminergic neurons: In vivo and in vitro.
    Wu L; Du ZR; Xu AL; Yan Z; Xiao HH; Wong MS; Yao XS; Chen WF
    Biomed Pharmacother; 2017 Jul; 91():656-663. PubMed ID: 28494419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRDX6 Exacerbates Dopaminergic Neurodegeneration in a MPTP Mouse Model of Parkinson's Disease.
    Yun HM; Choi DY; Oh KW; Hong JT
    Mol Neurobiol; 2015 Aug; 52(1):422-31. PubMed ID: 25193021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity by deprenyl in organotypic canine substantia nigra cultures.
    Schmidt DE; Ebert MH; Lynn JC; Whetsell WO
    J Neural Transm (Vienna); 1997; 104(8-9):875-85. PubMed ID: 9451719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental modeling of preclinical and clinical stages of Parkinson's disease.
    Khaindrava VG; Kozina EA; Kudrin VS; Kucheryanu VG; Klodt PD; Narkevich VB; Bocharov EV; Nanaev AK; Kryzhanovsky GN; Raevskii KS; Ugrumov MV
    Bull Exp Biol Med; 2011 Mar; 150(5):566-9. PubMed ID: 22235385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra.
    Ricaurte GA; Irwin I; Forno LS; DeLanney LE; Langston E; Langston JW
    Brain Res; 1987 Feb; 403(1):43-51. PubMed ID: 3493827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.
    Karunakaran S; Saeed U; Mishra M; Valli RK; Joshi SD; Meka DP; Seth P; Ravindranath V
    J Neurosci; 2008 Nov; 28(47):12500-9. PubMed ID: 19020042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte-macrophage colony-stimulating factor promotes survival of dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced murine Parkinson's disease model.
    Kim NK; Choi BH; Huang X; Snyder BJ; Bukhari S; Kong TH; Park H; Park HC; Park SR; Ha Y
    Eur J Neurosci; 2009 Mar; 29(5):891-900. PubMed ID: 19245369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration.
    Lee E; Hwang I; Park S; Hong S; Hwang B; Cho Y; Son J; Yu JW
    Cell Death Differ; 2019 Jan; 26(2):213-228. PubMed ID: 29786072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of natural resistance-associated macrophage protein-1 (Nramp1) is associated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/1-methyl-4-phenylpyridinium (MPP
    Wu KC; Liou HH; Lee CY; Lin CJ
    Neuropathol Appl Neurobiol; 2019 Feb; 45(2):157-173. PubMed ID: 29679389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
    Saporito MS; Brown EM; Miller MS; Carswell S
    J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electroacupuncture Promotes Recovery of Motor Function and Reduces Dopaminergic Neuron Degeneration in Rodent Models of Parkinson's Disease.
    Lin JG; Chen CJ; Yang HB; Chen YH; Hung SY
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects.
    Yao L; Li W; She H; Dou J; Jia L; He Y; Yang Q; Zhu J; Cápiro NL; Walker DI; Pennell KD; Pang Y; Liu Y; Han Y; Mao Z
    J Biol Chem; 2012 Oct; 287(41):34246-55. PubMed ID: 22891246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.